AMPEAmpio Pharmaceuticals, Inc.

About Ampio Pharmaceuticals, Inc. (AMPE)

Ampio Pharmaceuticals, Inc. (AMPE) is a Biotechnology company headquartered in Englewood, CO, United States whose shares trade over-the-counter on the Expert Market tier.

Ampio Pharmaceuticals, Inc. is a pre-revenue stage biopharmaceutical company focused on the development of a potential treatment for osteoarthritis as part of its OA-201 program. The OA-201 development program is seeking to advance Ampio's unique and proprietary small molecule formulation to take forward through pain and chondroprotection pre-clinical studies and the next phases of drug development. Ampio's primary strategy is to address the large and attractive opportunity for treatment of osteoarthritis of the knee ("OAK") and other joints.

Products and services

At this time, OA-201 is our only development program and the small molecule formulation is our only potential product in development. Any future product candidate will require additional development, which may include further non-clinical studies, as well as clinical trials, optimization of the formulation, and regulatory approvals, before they can be commercialized. Positive results obtained during early development do not necessarily mean later development will succeed.

AMPE key facts

Ticker symbol

AMPE

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Englewood, CO, United States

Country of incorporation

US

Year of incorporation

2010

Employees

6

Estimated market cap

$2.4K (as of Apr 15, 2025)

Shares outstanding

1,135,358

Reporting standard

Dark: Alternative Reporting Standard

Audit status

Audited

Fiscal year end

12/31

Ampio Pharmaceuticals, Inc. leadership

• Michael A. Martino — CEO
• Dan Stokely — CFO
• Beki Cleveland — Controller

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with A